Y Intercept Hong Kong Ltd Trims Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Y Intercept Hong Kong Ltd decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 92.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,190 shares of the medical equipment provider’s stock after selling 63,137 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Zimmer Biomet were worth $469,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Leonteq Securities AG lifted its holdings in Zimmer Biomet by 5.3% in the first quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock valued at $277,000 after acquiring an additional 153 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Zimmer Biomet by 43.7% during the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 33,847 shares of the medical equipment provider’s stock worth $3,060,000 after acquiring an additional 10,300 shares during the last quarter. Keybank National Association OH increased its stake in Zimmer Biomet by 7.4% during the first quarter. Keybank National Association OH now owns 14,107 shares of the medical equipment provider’s stock worth $1,276,000 after acquiring an additional 968 shares during the last quarter. Secured Retirement Advisors LLC raised its position in Zimmer Biomet by 2.0% in the first quarter. Secured Retirement Advisors LLC now owns 9,752 shares of the medical equipment provider’s stock valued at $882,000 after purchasing an additional 195 shares during the period. Finally, USS Investment Management Ltd lifted its stake in shares of Zimmer Biomet by 19.5% in the 1st quarter. USS Investment Management Ltd now owns 56,444 shares of the medical equipment provider’s stock valued at $5,105,000 after purchasing an additional 9,228 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $90.90 on Wednesday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The firm has a market cap of $17.59 billion, a PE ratio of 23.61, a price-to-earnings-growth ratio of 2.77 and a beta of 0.46. The company’s 50 day moving average is $86.65 and its two-hundred day moving average is $89.80.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same quarter in the previous year, the firm posted $1.81 earnings per share. The company’s quarterly revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a dividend of $0.24 per share. The ex-dividend date is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is 24.94%.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.28% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ZBH shares. Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Canaccord Genuity Group set a $83.00 target price on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Robert W. Baird set a $92.00 target price on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Wells Fargo & Company dropped their price target on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. Finally, Barclays reduced their price target on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $100.70.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.